Sugi Predict

Sugi Predict / Compounds / SCHEMBL19167409

SCHEMBL19167409

SCHEMBL19167409

c1ccc(-c2nc(-c3ccc(-c4ccc5ccc6cccc7ccc4c5c67)cc3)nc(-c3ccccc3-c3ccccn3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ SMN1; SMN2 Q16637 9/20 0.40
▸ TP53 P04637 6/20 0.40
▸ NPC1 O15118 5/20 0.40
▸ HSD17B10 Q99714 4/20 0.40
▸ HPGD P15428 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ MAPK1 P28482 3/20 0.40
▸ LMNA P02545 6/20 0.39
▸ RAB9A P51151 5/20 0.39
▸ PKM P14618 3/20 0.39
▸ TSHR P16473 3/20 0.39
▸ KLF5 Q13887 2/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP8 Q96LD8 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39
▸ GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19167412 0.95 KDM4E (0.42) KDM4ETDP1SMN1; SMN2TP53NPC1
SCHEMBL19167342 0.92 HSD17B10 (0.43) KDM4ETDP1SMN1; SMN2TP53NPC1
SCHEMBL19167414 0.91 SMN1; SMN2 (0.41) KDM4ETDP1SMN1; SMN2TP53NPC1
SCHEMBL19167665 0.91 HSD17B10 (0.40) KDM4ESMN1; SMN2TP53NPC1HSD17B10
SCHEMBL19168071 0.91 HSD17B10 (0.40) KDM4ESMN1; SMN2TP53NPC1HSD17B10
SCHEMBL19168474 0.90 HSD17B10 (0.39) KDM4ESMN1; SMN2TP53NPC1HSD17B10
SCHEMBL19167398 0.89 KDM4E (0.44) KDM4ETDP1SMN1; SMN2TP53NPC1
SCHEMBL19168198 0.88 SMN1; SMN2 (0.39) KDM4ETDP1SMN1; SMN2TP53NPC1
SCHEMBL19168095 0.86 HPGD (0.42) KDM4ESMN1; SMN2TP53NPC1HSD17B10
SCHEMBL19167646 0.86 HPGD (0.42) KDM4ESMN1; SMN2TP53NPC1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10797244-B2 Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2020-10-06 — — US disclosed
US-20170213982-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-07-27 — — US disclosed
US-20170213982-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10797244-B2 Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device RER1, RBM12, H1-2 KDM4E 2426/4885TDP1 3901/4885SMN1; SMN2 2023/4885
US-20170213982-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE RER1, RBM12, H1-2 KDM4E 2426/4885TDP1 3901/4885SMN1; SMN2 2023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.